- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06583525
Evaluation of the TAC Program
Evaluation of the Transition to Adult Care (TAC) Program for High-Risk Youth with Multimorbidity or Rare Disease: a Prospective Observation Cohort Study
This is a mixed-methods evaluative study examining the effectiveness of the Transition to Adult Care Program at the Hospital for Sick Children (TAC) Program on high-risk youth with medical and psychosocial complexity transitioning to adult and/or primary care services.
The overarching aim is to study the effectiveness of a new interdisciplinary and holistic Transition to Adult Care Program (TAC) on health-related outcomes for high-risk youth with multimorbidity or rare diseases and their caregivers by:
- Assess the effect of the TAC program on the youth's transition readiness, self-efficacy, self-management, health-related quality of life, and satisfaction.
- Assess the effect of the TAC program on the caregiver's satisfaction.
- Explore the experiences, perceptions, needs, and priorities of youth and caregivers participating in the TAC program using qualitative research methods.
- Describe the feasibility of the TAC program (defined as success in patient recruitment, attendance, participation, retention and transfer).
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Aged 16-18 years old and have a complex medical history, as defined by:
- Clinical Characteristics: Multi-morbidity (≥ 3 long-term chronic physical and/or mental health conditions (with primary condition being a physical health condition AND/OR Rare disease/ genetic condition.
- High Risk: No clearly identified adult provider/services following transfer AND/OR experiencing significant barriers related to Social and Structural Determinants of Health.
Exclusion Criteria:
- Moderate to severe developmental/intellectual disabilities
- Followed by services at SickKids which has an established transition program/provider
- Does not provide consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Early Identification and Transition Readiness
Time Frame: Baseline,12 months and 24 months
|
The change in the patients demonstration of their self-management skills and transition readiness will be assessed using the Transition Readiness Assessment Questionnaire (20-item survey).
A scoring of 4 or more across all domains is considered an indicator of transition readiness.
|
Baseline,12 months and 24 months
|
|
Early Identification and Transition Readiness
Time Frame: Baseline,12 months and 24 months
|
The change in the patients self-efficacy in their ability to manage their health and demonstrate transition readiness will be assessed using the General Self-Efficacy Scale (10 item survey).
A total score is achieved from a range of 10 to 40, with high scores as an indication of better perceived general self-efficacy.
|
Baseline,12 months and 24 months
|
|
Early Identification and Transition Readiness
Time Frame: Baseline,12 months and 24 months
|
The change in the patients knowledge and confidence in their ability to manage their health and demonstrate transition readiness will be assessed using the Patient Activation Measure (10-item survey).
An average net 6-point score increase demonstrating improvement
|
Baseline,12 months and 24 months
|
|
Early Identification and Transition Readiness - Service Satisfaction
Time Frame: Baseline,12 months and 24 months
|
The change in the patients and caregivers satisfaction with transitional health care services will be measured using the Larsen Client Satisfaction Questionnaire (8-item survey).
|
Baseline,12 months and 24 months
|
|
Information Sharing and Support
Time Frame: 6 to 24 months
|
The transition intervention will include providing the patients and caregivers with information on available needs-based services and support.
The number of patients who receive this intervention will be assessed via report in the patients medical record.
|
6 to 24 months
|
|
Information Sharing and Support
Time Frame: 6 to 24 months
|
The transition intervention will include offering support from the time of discharge from pediatric services until the first appointment with adult services.
The number of patients who receive this intervention will be assessed via report in the patients medical record.
|
6 to 24 months
|
|
Transition Plan
Time Frame: 6 to 24 months
|
The transition intervention will include the co-creating an individualized transition plan to identify the patients transition goals and set timelines.
The number of patients who receive this intervention will be assessed via report in the patients medical record.
|
6 to 24 months
|
|
Coordinated Transition
Time Frame: 6 to 24 months
|
The transition intervention will include developing a patient-specific transfer package.
The number of patients who receive this intervention will be assessed via report in the patients medical record.
|
6 to 24 months
|
|
Introduction to Adult Services
Time Frame: 24 to 36 months
|
A joint clinic visit will be facilitated by the transition team with the identified receiving adult care provider.
The number of patients who have received a warm handover visit with the transition team, primary care provider/service team, will be assessed via report in the patients medical record.
|
24 to 36 months
|
|
Transition Completion
Time Frame: 24 to 36 months
|
Successful transfer will be measured by the attendance of the first appointment with a primary care and/or subspecialty adult care provider between the first 6 to 12 months of transfer from the pediatric provider.
|
24 to 36 months
|
|
Health-Related Quality of Life
Time Frame: Baseline, 12 months and 24 months
|
The change in the patients quality of life will be measured using the The Pediatric Quality of Life Inventory 4.0 Generic Core Scale Teen Report The 23-item survey will assess four core health dimensions (physical functioning, emotional functioning, social functioning and school functioning) transformed into total scores ranging from 0 to 100.
An increase in 12 and 24 months follow-up scores from baseline will be measured.
|
Baseline, 12 months and 24 months
|
|
Experience in the process
Time Frame: 24 to 36 months
|
Semi-structured qualitative interviews will be conducted with a subset of participants to explore participants; experiences working with the transition team, and satisfaction with the tools and resources used.
|
24 to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Program Feasibility
Time Frame: 24 to 36 months
|
The successful implementation of the intervention will be evaluated by assessing the feasibility of the program.
The percentage of attended appointments, completed questionnaires, individualized transition plans created, warm handovers completed prior to participants' 18th birthday, and additional clinic visits required will be documented for each participant.
|
24 to 36 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 1000081574
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Youth with Multimorbidity or Rare Dieases
-
Duke UniversityBoston Children's HospitalCompletedChildren/Youth With Special Healthcare Needs | Adults With Multiple Chronic ConditionsUnited States
-
University of FloridaDiabetes Action Research and Education FoundationCompletedArterial Stiffness in Youth With Type 1 DiabetesUnited States
-
University of California, IrvineCompletedBarrett's Esophagus With or Without Dysplasia | Patients With Early Esophageal or Gastric Cancer | Patients With Intestinal Metaplasia of the StomachUnited States
-
Taiho Oncology, Inc.TerminatedAdvanced Solid Tumors With HER2 Abnormalities | Advanced Solid Tumors With HER3 AbnormalitiesUnited States, Spain, France, United Kingdom
-
Servier Bio-Innovation LLCInstitut de Recherches Internationales ServierRecruitingLocally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment RegimenUnited States, France, Germany, Netherlands, Spain, China, Japan, United Kingdom, Canada, Australia, Brazil, Italy, Taiwan, Denmark, Puerto Rico, South Korea, Belgium
-
Novartis PharmaceuticalsTerminatedCeritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (SIGNATURE)Tumors With Aberrations in ALK or ROS1United States
-
PfizerTerminatedAvelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid TumorsUnited States, Canada, United Kingdom, Korea, Republic of, Australia, Belgium, Denmark, Hungary, Russian Federation
-
Asan Medical CenterActive, not recruitingSubjects With Resectable and Localized Gastric Cancer | Subjects With Resectable Esophageal Cancer or Liver Cancer | Subjects With Resectable Liver CancerSouth Korea
-
Catalyst BiosciencesTerminatedPrevious Diagnosis With a Complement-mediated Disease and/or With Clinical Manifestations Reasonably Associated With Complement Factor I DeficiencyUnited States
-
Xiyuan Hospital of China Academy of Chinese Medical...UnknownRehabilitation With CHF; NYHA Class I or IIChina